1. |
Zhang L, Li Y, Hu C, et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol Cancer 2022; 21:103. doi: 10.1186/s12943-022-01524-w.
|
2. |
Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55:3-29. doi: 10.1016/s0169-409x(02)00169-2.
|
3. |
Katoh SY, Ueno M, Takakura N. Involvement of MDR1 function in proliferation of tumour cells. J Biochem 2008; 143:517-24. doi: 10.1093/jb/mvm242.
|
4. |
Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998; 95:7024-9. doi: 10.1073/pnas.95.12.7024.
pmid: 9618532
|
5. |
Tao LY, Liang YJ, Wang F, et al. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 2009; 64:961-9. doi: 10.1007/s00280-009-0949-1.
|
6. |
Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009; 109:2989-3011. doi: 10.1021/cr9000226.
pmid: 19583429
|
7. |
Dong XD, Zhang M, Ma X, et al. Bruton’s tyrosine kinase (BTK) inhibitor RN486 overcomes ABCB1-mediated multidrug resistance in cancer cells. Front Cell Dev Biol 2020; 8:865. doi: 10.3389/fcell.2020.00865.
|
8. |
Zou T, Zeng C, Qu J, et al. Rutaecarpine increases anticancer drug sensitivity in drug-resistant cells through MARCH8-dependent ABCB1 degradation. Biomedicines 2021; 9(9):1143. doi: 10.3390/biomedicines9091143.
|
9. |
Wu X, Yin C, Ma J, et al. Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo. Acta Pharm Sin B 2021; 11(7):1885-902. doi: 10.1016/j.apsb.2020.12.021.
|
10. |
Zhou HH, Chen X, Cai LY, et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front Oncol 2019; 9:1398. doi: 10.3389/fonc.2019.01398.
|
11. |
Luo X, Teng QX, Dong JY, et al. Antimicrobial peptide reverses ABCB1-mediated chemotherapeutic drug resistance. Front Pharmacol 2020; 11:1208. doi: 10.3389/fphar.2020.01208.
pmid: 32903706
|
12. |
Cheng Y, Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. JBC 1998; 273(52):35008-15. doi: 10.1074/jbc.273.52.35008.
|
13. |
Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 2007; 99(22):1668-82. doi: 10.1093/jnci/djm208.
pmid: 18000218
|
14. |
Xu J, Tian J, Shapiro SD. Normal lung development in RAIG1-deficient mice despite unique lung epithelium-specific expression. Am J Respir Cell Mol Biol 2005; 32(5):381-7. doi: 10.1165/rcmb.2004-0343OC.
|
15. |
Song H, Ye X, Liao Y, et al. NF-κB represses retinoic acid receptor-mediated GPRC5A transactivation in lung epithelial cells to promote neoplasia. JCI Insight 2023; 8(1):e153976. doi: 10.1172/jci.insight.153976.
|
16. |
Zhong S, Yin H, Liao Y, et al. Lung tumor suppressor GPRC5A binds EGFR and restrains its effector signaling. Cancer Res 2015; 75(9):1801-14. doi: 10.1158/0008-5472.CAN-14-2005.
pmid: 25744720
|
17. |
Wang T, Jing B, Xu D, et al. PTGES/PGE(2) signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model. Oncogene 2020; 39(15):3179-94. doi: 10.1038/s41388-020-1207-6.
|
18. |
Olarte Carrillo I, García Laguna AI, De la Cruz Rosas A, et al. High expression levels and the C3435T SNP of the ABCB 1 gene are associated with lower survival in adult patients with acute myeloblastic leukemia in Mexico City. BMC Med Genomics 2021; 14(1):251. doi: 10.1186/s12920-021-01101-y.
|
19. |
Jadhao M, Tsai EM, Yang HC, et al. The long-term DEHP exposure confers multidrug resistance of triple-negative breast cancer cells through ABC transporters and intracellular ROS. Antioxidants (Basel, Switzerland) 2021; 10(6): 102021. doi: 10.3390/antiox10060949.
|
20. |
Goto S, Kawabata T, Li TS. Enhanced expression of ABCB1 and Nrf2 in CD133-positive cancer stem cells associates with doxorubicin resistance. Stem Cells Int 2020; 2020:8868849. doi: 10.1155/2020/8868849.
|
21. |
Nasir A, Cardall A, Othman RT, et al. ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Neurooncol Adv 2021; 3(1):vdab030. doi: 10.1093/noajnl/vdab030.
|
22. |
Liu D, Jin Y, Wu J, et al. MiR-135b-5p is an oncogene in pancreatic cancer to regulate GPRC5A expression by targeting transcription factor KLF4. Cell Death Discov 2022; 8(1):23. doi: 10.1038/s41420-022-00814-y.
|
23. |
Sokolenko AP, Bulanova DR, Iyevleva AG, et al. High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. Int J Cancer 2014; 134(10):2352-8.. doi: 10.1002/ijc.28569.
|
24. |
Ufer M, Hasler R, Jacobs G, et al. Decreased sigmoidal ABCB 1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics 2009; 10(12):1941-53. doi: 10.2217/pgs.09.128.
|
25. |
Nagahata T, Sato T, Tomura A, et al. Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer 2005; 12(1):65-73. doi: 10.1677/erc.1.00890.
|
26. |
Zhou H, Rigoutsos I. The emerging roles of GPRC5A in diseases. Oncoscience 2012; 1(12):765-76. doi: 10.18632/oncoscience.104.
|
27. |
Yang L, Zhao S, Zhu T, et al. GPRC5A is a negative regulator of the pro-survival PI3K/Akt signaling pathway in triple-negative breast cancer. Front Oncol 2020; 10:624493. doi: 10.3389/fonc.2020.624493.
|